Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
US-based ocular disorder treatment developer LumiThera reached the second close of its series C round on Monday having raised more than $10m from investors including optics technology producer and distribution partner Nikon Corporation. The round is being led by venture capital fund WaterStar Capital and follows a $5.5m series B featuring WaterStone Capital and RPR Venture in 2017. LumiThera has now raised a total of more than $19m in equity and convertible note financing according to press releases and securities…
